Home›Stock Screener›Piramal Pharma›Intrinsic Value

Piramal Pharma Intrinsic Value

Piramal Pharma intrinsic value. Piramal Pharma (PPLPHARMA) median intrinsic value is ₹121.18 from 8 valuation models (range ₹72–₹169), vs current price ₹239.65 — -49.4% downside (Trading Above Calculated Value), margin of safety -97.8%. Analyse Piramal Pharma ownership structure to track promoter, FII and institutional holdings.

Market Price (CMP)
₹239.65
Primary Intrinsic Value
₹71.89
Market Cap
₹318.0K Cr
-49.4% Downside
Median Value
₹121.18
Value Range
₹72 - ₹169
Assessment
Trading Above Calculated Value
Safety Margin
-97.8%

PPLPHARMA Valuation Methods Summary — DCF, Graham Number & P/E

Piramal Pharma intrinsic value across 8 models vs current price ₹239.65 — upside/downside and value range per method. For current market price and key ratios, visit Piramal Pharma share price screener.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹71.89 ₹57.51 - ₹86.27 -70.0% EPS: ₹0.16, Sector P/E: 22x
Book Value Method asset ₹123.03 ₹110.73 - ₹135.33 -48.7% Book Value/Share: ₹61.51, P/B: 2.0x
Revenue Multiple Method revenue ₹161.02 ₹144.92 - ₹177.12 -32.8% Revenue/Share: ₹80.51, P/S: 2.0x
EBITDA Multiple Method earnings ₹121.18 ₹109.06 - ₹133.30 -49.4% EBITDA: ₹1608.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹169.20 ₹135.36 - ₹203.04 -29.4% CF Growth: 15.0%, Discount: 15%
PEG Ratio Method growth ₹71.89 ₹64.70 - ₹79.08 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹71.89 ₹64.70 - ₹79.08 -70.0% Revenue Growth: 6.0%, Adj P/E: 15.5x
Graham Defensive Method conservative ₹71.89 ₹64.70 - ₹79.08 -70.0% EPS: ₹0.16, BVPS: ₹61.51
Method Types: Earnings Asset DCF Growth Dividend Conservative

PPLPHARMA Intrinsic Value vs Market Price — All Valuation Models

Piramal Pharma fair value range ₹72–₹169 vs current market price ₹239.65 across 8 valuation models. Browse PPLPHARMA cash flow statement for revenue, profit, balance sheet and cash flow data.

PPLPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?

Piramal Pharma median intrinsic value ₹121.18, current price ₹239.65 — Trading Above Calculated Value by 49.4%, margin of safety -97.8%.

What is the intrinsic value of PPLPHARMA?

Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Piramal Pharma (PPLPHARMA) is ₹121.18 (median value). With the current market price of ₹239.65, this represents a -49.4% variance from our estimated fair value.

The valuation range spans from ₹71.89 to ₹169.20, indicating ₹71.89 - ₹169.20.

Is PPLPHARMA undervalued or overvalued?

Based on our multi-method analysis, Piramal Pharma (PPLPHARMA) appears to be trading above calculated value by approximately 49.4%.

PPLPHARMA Financial Health — Key Ratios vs Industry Benchmarks

Piramal Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 0.2% Industry Standard: 15%+ Below 10% Measures shareholder return efficiency
Operating Margin 13.0% Industry Standard: 20%+ Above 10% Indicates operational efficiency level
Asset Turnover Ratio 0.59x Industry Standard: 1.0x+ Above 0.5x Measures asset utilization efficiency

PPLPHARMA Cash Flow Quality — Operating & Free Cash Flow

Piramal Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹1,653 Cr ₹1,243 Cr Positive Free Cash Flow 8/10
March 2025 ₹892 Cr ₹648 Cr Positive Free Cash Flow 8/10
March 2024 ₹1,005 Cr ₹797 Cr Positive Free Cash Flow 8/10
March 2023 ₹484 Cr ₹-183 Cr Positive Operating Cash Flow 6/10
March 2022 ₹766 Cr ₹-103 Cr Positive Operating Cash Flow 6/10